Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VRK1 | Q99986 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12169267 | 0.82 | GABRA1 (0.32) | GABRA1GABRB2CPB2 | |
| SCHEMBL17229260 | 0.80 | CYP2A6 (0.34) | GABRA1GABRB2CPB2NOS3NOS1 | |
| SCHEMBL30868178 | 0.79 | CPB2 (0.48) | VRK1GABRA1GABRB2CPB2NOS3 | |
| SCHEMBL21503664 | 0.79 | ALDH1A1 (0.33) | GABRA1GABRB2CPB2SMN1; SMN2 | |
| SCHEMBL17553917 | 0.78 | VRK1 (0.35) | VRK1NOS3NOS1NOS2KDM4E | |
| SCHEMBL17229282 | 0.77 | S1PR1 (0.33) | GABRA1GABRB2CPB2NOS3NOS1 | |
| SCHEMBL17229318 | 0.77 | CHRNB2 (0.37) | GABRA1GABRB2CPB2NOS3NOS1 | |
| SCHEMBL21503624 | 0.77 | PPARD (0.30) | — | |
| SCHEMBL23564745 | 0.76 | LOXL2 (0.39) | VRK1KDM4ESMN1; SMN2 | |
| SCHEMBL335538 | 0.76 | VRK1 (0.38) | VRK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | VRK1 2787/4885GABRA1 3502/4885GABRB2 4068/4885 |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | VRK1 4492/4885GABRA1 874/4885GABRB2 269/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | VRK1 2787/4885GABRA1 3502/4885GABRB2 4068/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | VRK1 2787/4885GABRA1 3502/4885GABRB2 4068/4885 |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | VRK1 4401/4885GABRA1 989/4885GABRB2 286/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | VRK1 2787/4885GABRA1 3502/4885GABRB2 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.